Systemic Anti-Cancer Therapy Regimen Library
LYM - vinORELBine and gemcitabine
Treatment Overview
Usually 4 to 6 cycles.
This regimen contains a medicine where one or more biosimilars may exist. Any biosimilars used have been reviewed by the regulator (Medsafe) and relevant specialists were consulted nationally. Where regulators, in consultation with relevant specialists, have agreed that there are no clinically significant differences in either safety or effectiveness between a biosimilar and originator product, these drugs may be used interchangeably.
Cycles 1 to 6 - 21 days
Some centres may choose to include a steroid (e.g. dexamethasone) with this regimen.
Cycle details
Cycles 1 to 6 - 21 days
| Medication | Dose | Route | Days | Max Duration |
|---|---|---|---|---|
| vinORELBine * | 25 mg/m² | intravenous | 1, 8 | 10 minutes |
| gemcitabine * | 1000 mg/m² | intravenous | 1, 8 | 30 minutes |
Some centres may choose to include a steroid (e.g. dexamethasone) with this regimen.
Full details
Cycles 1 to 6 - 21 days
Day: 1
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| vinORELBine * | 25 mg/m² | intravenous | 10 minutes |
Instructions:
|
| gemcitabine * | 1000 mg/m² | intravenous | 30 minutes |
Day: 8
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| vinORELBine * | 25 mg/m² | intravenous | 10 minutes |
Instructions:
|
| gemcitabine * | 1000 mg/m² | intravenous | 30 minutes |
Supportive Care Factors
| Factor | Value |
|---|---|
| Antiviral prophylaxis for herpes virus: | Routine antiviral prophylaxis may be considered |
| Constipation risk: | laxatives are usually prescribed |
| Emetogenicity: | Low |
| Growth factor support: | Variable |
| Irradiated blood components: | Variable |
| Tumour lysis syndrome prophylaxis: | Tumour lysis syndrome prophylaxis may be considered |
Antiviral prophylaxis for hepatitis B virus: Guidance is limited to high-risk anti-cancer medicines. Clinicians will need to assess individual patient risk for other anti-cancer medicines.
Growth factor support: Consider primary prophylaxis for patients over 64 years of age or other high-risk patients.
Irradiated blood components: Required for Hodgkin lymphoma patients at all stages of disease and therapy. Continue indefinitely.
References
New Zealand Blood Service Transfusion Medicine Handbook Third Edition, 2016 https://www.nzblood.co.nz/assets/Transfusion-Medicine/PDFs/111G122.pdf (accessed 16 June 2022).
* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.
s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.